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Background
Thalidomide has proven to exert anti-inflammatory, anti-
proliferative and anti-angiogenic activities in both neo-
plastic and non-neoplastic conditions. We investigated
the effects of this compound on blood vessel formation,
inflammatory cell recruitment/activation and cytokine
production of 4T1 mammary tumor in mice.
Materials and methods
4T1 cells were injected subcutaneously into Balb/c mice.
After tumor engraftment (5 days), thalidomide (150
mg/kg) was administered to the treated group for 7 days.
Tumors of control and treated groups were sized regularly,
removed 12 days after inoculation and processed for bio-
chemical parameters to assess neovascularization and
inflammation.
Results
Daily oral dose of thalidomide was able to reduce in 46%
the tumor volume. Assessment of tumor vascularization
revealed a significant decrease in blood vessels formation
by thalidomide. The levels of two cytokines, VEGF and
TNF-a were decreased in tumor samples of thalidomide-
treated group compared with the control group. Accumu-
lation of neutrophils or macrophages in the 4T1 tumor
measured by the activities of inflammatory enzymes, MPO
for neutrophils and NAG for macrophages, was inhibited
by the treatment.
Conclusions
By targeting key components of 4T1 tumor simulta-
neously, thalidomide was effective in attenuating tumor
growth. This approach, suppression of inflammation and
angiogenesis may provide further insights for both preven-
tion and treatment of cancer.
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